- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Why PSMA imaging is unique from other prostate cancer imaging technologies
We've never had an imaging agent like this before,” says Leonard S. Marks, MD.
In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
